Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTb), remains a global health challenge, with treatment involving a year-long regimen of four drugs: Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol. However, the emergence of drug resistance calls for the development of new therapeutic molecules. Due to the complex granulomatous lesions formed by MTb, plasma drug concentrations often do not reflect tissue drug levels, making it crucial to assess drug exposure at the site of action. To address this, we have developed Mass Spectrometry Imaging (MSI) methods to study the distribution of anti-TB drugs and their metabolites, including pyrazinoic acid, across both healthy and diseased tissues.
Download our poster to learn more.